Transplantační medicína

Type 1 diabetes (T1D) is a progressive disease in which the decline in beta cell function usually begins months or sometimes years before clinical symptoms are observed.^1–3 You can identify such patients at risk of developing T1D before clinical symptoms are noticed by you or your patient.³

The progression of type 1 diabetes (T1D) is gradual, often detectable months or even years before symptoms arise.^1–3 Through proactive screening, the condition can be identified well in advance.³ Meet our ambassadors living with T1D and discover the risk factors to look out for when considering who to screen.

Delay in screening for type 1 diabetes (T1D) can increase the risk of diabetic ketoacidosis (DKA) at diagnosis—a critical complication that is potentially life-threatening and may result in long-term poor glycemic control and neurological complications.^1,2 By identifying T1D early, you can significantly lower the risk of DKA at diagnosis.^3,4

Individuals who screen positive for ≥1 autoimmune islet cell antibodies need periodic medical monitoring, which includes regular assessments of blood glucose and HbA1c levels. You can also educate them about symptoms of diabetes, diabetic ketoacidosis (DKA), and provide psychosocial support to prepare them for a possible clinical diagnosis for type 1 diabetes (T1D).¹

Individuals living with other associated autoimmune diseases like coeliac disease or autoimmune thyroid disease, are at an increased risk of developing type 1 diabetes (T1D) and should be appropriately screened.^1-6

Anti-islet autoantibodies that target proteins associated with beta-cells serve as biomarkers of type 1 diabetes (T1D) development.¹ The number of detectable autoantibodies through screening correlates with risk of developing T1D.² Assays for detecting T1D have shown high sensitivity and specificity.^3,4  

Type 1 diabetes (T1D) is a progressive disease in which the decline in beta cell function usually begins months or sometimes years before clinical symptoms are observed.^1–3 You can identify such patients at risk of developing T1D before clinical symptoms are noticed by you or your patient.³

Anti-islet autoantibodies that target proteins associated with beta-cells serve as biomarkers of type 1 diabetes (T1D) development.¹ The number of detectable autoantibodies through screening correlates with risk of developing T1D.² Assays for detecting T1D have shown high sensitivity and specificity.^3,4  

Individuals living with other associated autoimmune diseases like coeliac disease or autoimmune thyroid disease, are at an increased risk of developing type 1 diabetes (T1D) and should be appropriately screened.^1-6

The progression of type 1 diabetes (T1D) is gradual, often detectable months or even years before symptoms arise.^1–3 Through proactive screening, the condition can be identified well in advance.³ Meet our ambassadors living with T1D and discover the risk factors to look out for when considering who to screen.

Delay in screening for type 1 diabetes (T1D) can increase the risk of diabetic ketoacidosis (DKA) at diagnosis—a critical complication that is potentially life-threatening and may result in long-term poor glycemic control and neurological complications.^1,2 By identifying T1D early, you can significantly lower the risk of DKA at diagnosis.^3,4

Individuals who screen positive for ≥1 autoimmune islet cell antibodies need periodic medical monitoring, which includes regular assessments of blood glucose and HbA1c levels. You can also educate them about symptoms of diabetes, diabetic ketoacidosis (DKA), and provide psychosocial support to prepare them for a possible clinical diagnosis for type 1 diabetes (T1D).¹